Evidence map›Paper›PMID 35468205›Full record

ArticleNeuro-oncology2022

Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell-mediated toxicity against glioblastoma.

Ruichong Ma, Margarida Rei, Isaac Woodhouse, Katherine Ferris, Sophie Kirschner, Anandhakumar Chandran, Uzi Gileadi, Ji-Li Chen, Mariana Pereira Pinho, Yoanna Ariosa-Morejon and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. ZP4: A novel target for CAR-T cell therapy in triple negative breast cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Ruichong MaMRC Human Immunology Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-4939-8553
Margarida ReiMRC Human Immunology Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Isaac WoodhouseMRC Human Immunology Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Katherine FerrisMRC Human Immunology Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Sophie KirschnerLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Anandhakumar ChandranLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Uzi GileadiMRC Human Immunology Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Ji-Li ChenMRC Human Immunology Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Mariana Pereira PinhoMRC Human Immunology Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Yoanna Ariosa-MorejonCentre for Cellular and Medical Physiology, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Skirmantas KriaucionisLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Nicola TernetteCentre for Cellular and Medical Physiology, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Hashem KoohyMRC Human Immunology Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-3640-7043
Olaf AnsorgeNuffield Department of Clinical Neurosciences, University of Oxford, UK.
Graham OggMRC Human Immunology Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Puneet PlahaDepartment of Neurosurgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Vincenzo CerundoloMRC Human Immunology Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
University of Oxford · GB

Funding

Medical Research Council MC_UU_00008/5
6 · The paper itself

Abstract

backgroundGlioblastoma (GBM) is the most common and malignant primary brain tumor in adults. Despite maximal treatment, median survival remains dismal at 14-24 months. Immunotherapies, such as checkpoint inhibition, have revolutionized management of some cancers but have little benefit for GBM patients. This is, in part, due to the low mutational and neoantigen burden in this immunogenically "cold" tumor.

methodsU87MG and patient-derived cell lines were treated with 5-aza-2'-deoxycytidine (DAC) and underwent whole-exome and transcriptome sequencing. Cell lines were then subjected to cellular assays with neoantigen and cancer testis antigen (CTA) specific T cells.

resultsWe demonstrate that DAC increases neoantigen and CTA mRNA expression through DNA hypomethylation. This results in increased neoantigen presentation by MHC class I in tumor cells, leading to increased neoantigen- and CTA-specific T-cell activation and killing of DAC-treated cancer cells. In addition, we show that patients have endogenous cancer-specific T cells in both tumor and blood, which show increased tumor-specific activation in the presence of DAC-treated cells.

conclusionsOur work shows that DAC increases GBM immunogenicity and consequent susceptibility to T-cell responses in vitro. Our results support a potential use of DAC as a sensitizing agent for immunotherapy.

Indexed as

GlioblastomaAdultAntigens, NeoplasmCell Line, TumorDecitabineHumansMaleTestisT-LymphocytesAntigens, NeoplasmDecitabinedecitabineglioblastomaimmunotherapyneoantigentumor immunology

Identifiers

PMID35468205
PMCPMC9713507
OpenAlexW4224944457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.